

MSN Marks Major Milestone with U.S. Launch of Sacubitril and Valsartan Tablets Following Hard-Fought Legal Victory

New Jersey – 19th August, 2025 – MSN Pharmaceuticals, the U.S. subsidiary of global pharmaceutical leader MSN Group, is pleased to announce the launch of its generic Sacubitril+Valsartan Tablets in the United States, which is indicated to reduce the risk of cardiovascular death and hospitalization for adult patients with chronic heart failure and reduced ejection fraction. This marks a significant achievement in MSN's journey to expand access to affordable, high-quality cardiovascular medications for patients across the country.

Sacubitril and Valsartan Tablets is an important combination therapy widely used in the management of chronic heart failure with reduced ejection fraction. It helps to reduce the risk of cardiovascular death and hospitalizations, offering hope and an improved quality of life to patients throughout the United States.

MSN's path to launch was shaped by a rigorous legal and regulatory process. The company was at the forefront of a complex patent litigation that spanned multiple years. Despite facing multiple legal obstacles, including attempts to delay the approvals and launch of the product, MSN remained committed to its mission and engaged in a principled defence of its right to be first to introduce its cost effective generic product.

Throughout this process, MSN Pharmaceuticals worked in close coordination with regulatory authorities and adhered to the highest standards of legal compliance and product quality. After multiple court hearings, temporary injunctions, and legal appeals, MSN ultimately secured the necessary approvals to bring its Sacubitril and Valsartan tablets to the U.S. market.

“This launch stands as a symbol of our perseverance, integrity, and unwavering belief that lifesaving medicines must be accessible to all. Aligned with the U.S. government's vision and policy of promoting reduced drug prices through the promotion of robust generic pharmaceutical competition, this milestone reflects our enduring commitment to strengthening global healthcare access through our facilities in the USA as well” **MSN Pharmaceuticals said in a statement.**

MSN Group is among the fastest-growing, fully integrated pharma companies with 25 state-of-the-art facilities in India and the USA. Its unified R&D drives both APIs and finished dosage research. With 1000+ patents, 200+ ANDAs, and the world's No.1 position in US DMF filings, MSN offers 500+ APIs and 400+ finished dosages across 35+ therapeutic areas, serving 50M+ patients in 100+ countries with speed, reliability, and trust.